@article{MTMT:34165889,
	title = {Repositioning of HMG-CoA Reductase Inhibitors as Adjuvants in the Modulation of Efflux Pump-Mediated Bacterial and Tumor Resistance},
	url = {https://m2.mtmt.hu/api/publication/34165889},
	author = {Schelz, Zsuzsanna and Abdallah, Hiba Faroug Muddather and Zupkó, István},
	doi = {10.3390/antibiotics12091468},
	journal-iso = {ANTIBIOTICS-BASEL},
	journal = {ANTIBIOTICS},
	volume = {12},
	unique-id = {34165889},
	issn = {2079-6382},
	abstract = {Efflux pump (EP)-mediated multidrug resistance (MDR) seems ubiquitous in bacterial infections and neoplastic diseases. The diversity and lack of specificity of these efflux mechanisms raise a great obstacle in developing drugs that modulate efflux pumps. Since developing novel chemotherapeutic drugs requires large investments, drug repurposing offers a new approach that can provide alternatives as adjuvants in treating resistant microbial infections and progressive cancerous diseases. Hydroxy-methyl-glutaryl coenzyme-A (HMG-CoA) reductase inhibitors, also known as statins, are promising agents in this respect. Originally, statins were used in the therapy of dyslipidemia and for the prevention of cardiovascular diseases; however, extensive research has recently been performed to elucidate the functions of statins in bacterial infections and cancers. The mevalonate pathway is essential in the posttranslational modification of proteins related to vital eukaryotic cell functions. In this article, a comparative review is given about the possible role of HMG-CoA reductase inhibitors in managing diseases of bacterial and neoplastic origin. Molecular research and clinical studies have proven the justification of statins in this field. Further well-designed clinical trials are urged to clarify the significance of the contribution of statins to the lower risk of disease progression in bacterial infections and cancerous diseases.},
	keywords = {Statins; Mevalonate pathway; drug repositioning; HMG-COA REDUCTASE INHIBITORS; Reversal of multidrug resistance; efflux-mediated multidrug resistance; isoprenoid synthesis},
	year = {2023},
	eissn = {2079-6382},
	orcid-numbers = {Schelz, Zsuzsanna/0000-0002-8519-4830; Zupkó, István/0000-0003-3243-5300}
}

@article{MTMT:32287706,
	title = {Exploring the Monoterpene Indole Alkaloid Scaffold for Reversing P-Glycoprotein-Mediated Multidrug Resistance in Cancer},
	url = {https://m2.mtmt.hu/api/publication/32287706},
	author = {Cardoso, David and Szemerédi, Nikoletta and Spengler, Gabriella and Mulhovo, Silva and dos Santos, Daniel and Ferreira, Maria-José},
	doi = {10.3390/ph14090862},
	journal-iso = {PHARMACEUTICALS-BASE},
	journal = {PHARMACEUTICALS},
	volume = {14},
	unique-id = {32287706},
	abstract = {Dregamine (1), a major monoterpene indole alkaloid isolated from Tabernaemontana elegans, was submitted to chemical transformation of the ketone function, yielding 19 azines (3-21) and 11 semicarbazones (22-32) bearing aliphatic or aromatic substituents. Their structures were assigned mainly by 1D and 2D NMR (COSY, HMQC, and HMBC) experiments. Compounds 3-32 were evaluated as multidrug resistance (MDR) reversers through functional and chemosensitivity assays in a human ABCB1-transfected mouse T-lymphoma cell model, overexpressing P-glycoprotein. A significant increase of P-gp inhibitory activity was observed for most derivatives, mainly those containing azine moieties with aromatic substituents. Compounds with trimethoxyphenyl (17) or naphthyl motifs (18, 19) were among the most active, exhibiting strong inhibition at 0.2 mu M. Moreover, most of the derivatives showed selective antiproliferative effects toward resistant cells, having a collateral sensitivity effect. In drug combination assays, all compounds showed to interact synergistically with doxorubicin. Selected compounds (12, 17, 18, 20, and 29) were evaluated in the ATPase activity assay, in which all compounds but 12 behaved as inhibitors. To gather further insights on drug-receptor interactions, in silico studies were also addressed. A QSAR model allowed us to deduce that compounds bearing bulky and lipophilic substituents were stronger P-gp inhibitors.},
	keywords = {multidrug resistance; INDOLE ALKALOIDS; Molecular docking; ATPASE ACTIVITY; Tabernaemontana elegans; QSAR MODELS},
	year = {2021},
	eissn = {1424-8247},
	orcid-numbers = {Cardoso, David/0000-0002-8270-4276; Spengler, Gabriella/0000-0001-8085-0950; Ferreira, Maria-José/0000-0002-8742-1486}
}

@article{MTMT:32201163,
	title = {Cyano- and Ketone-Containing Selenoesters as Multi-Target Compounds against Resistant Cancers},
	url = {https://m2.mtmt.hu/api/publication/32201163},
	author = {Szemerédi, Nikoletta and Dobiasová, Simona and Salardón-Jiménez, Noemi and Kincses, Annamária and Nové, Márta and Habibullah, Giyaullah and Sevilla-Hernández, Clotilde and Benito-Lama, Miguel and Alonso-Martínez, Francisco-Javier and Viktorová, Jitka and Spengler, Gabriella and Domínguez-Álvarez, Enrique},
	doi = {10.3390/cancers13184563},
	journal-iso = {CANCERS},
	journal = {CANCERS},
	volume = {13},
	unique-id = {32201163},
	year = {2021},
	eissn = {2072-6694},
	orcid-numbers = {Salardón-Jiménez, Noemi/0000-0002-2215-804X; Kincses, Annamária/0000-0002-1591-1419; Habibullah, Giyaullah/0000-0001-9455-655X; Sevilla-Hernández, Clotilde/0000-0002-0745-5281; Viktorová, Jitka/0000-0003-0857-153X; Spengler, Gabriella/0000-0001-8085-0950; Domínguez-Álvarez, Enrique/0000-0003-2655-1575}
}

@article{MTMT:35236916,
	title = {ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer},
	url = {https://m2.mtmt.hu/api/publication/35236916},
	author = {van Geldermalsen, M. and Wang, Q. and Nagarajah, R. and Marshall, A. D. and Thoeng, A. and Gao, D. and Ritchie, W. and Feng, Y. and Bailey, C. G. and Deng, N. and Harvey, K. and Beith, J. M. and Selinger, C. I. and O'Toole, S. A. and Rasko, John and Holst, J.},
	doi = {10.1038/onc.2015.381},
	journal-iso = {ONCOGENE},
	journal = {ONCOGENE},
	volume = {35},
	unique-id = {35236916},
	issn = {0950-9232},
	year = {2016},
	eissn = {1476-5594},
	pages = {3201-3208},
	orcid-numbers = {Rasko, John/0000-0003-2975-807X}
}

@article{MTMT:2460237,
	title = {Age at Menarche and Menopause and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study},
	url = {https://m2.mtmt.hu/api/publication/2460237},
	author = {Chang-Claude, J and Andrieu, N and Rookus, M and Brohet, R and Antoniou, AC and Peock, S and Davidson, R and Izatt, L and Cole, T and Nogue`s C, . and Luporsi, E and Huiart, L and Hoogerbrugge, N and Van, Leeuwen FE and Osorio, A and Eyfjord, J and Radice, P and Goldgar, DE and Easton, DF and Oláh, Edit},
	doi = {10.1158/1055-9965.EPI-06-0829},
	journal-iso = {CANCER EPIDEM BIOMAR},
	journal = {CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION},
	volume = {16},
	unique-id = {2460237},
	issn = {1055-9965},
	year = {2007},
	eissn = {1538-7755},
	pages = {740-746}
}

@article{MTMT:151634,
	title = {Targeting multidrug resistance in cancer},
	url = {https://m2.mtmt.hu/api/publication/151634},
	author = {Szakács, Gergely and Paterson, JK and Ludwig, JA and Booth-Genthe, C and Gottesman, MM},
	doi = {10.1038/nrd1984},
	journal-iso = {NAT REV DRUG DISCOV},
	journal = {NATURE REVIEWS DRUG DISCOVERY},
	volume = {5},
	unique-id = {151634},
	issn = {1474-1776},
	year = {2006},
	eissn = {1474-1784},
	pages = {219-234}
}